Compare iShares MSCI South Korea ETF (EWY) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Korea ETF vs Merck & Co., Inc. — how do they compare? iShares MSCI South Korea ETF trades at $177.28 (market cap $26.25B), while Merck & Co., Inc. trades at $145.6 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 13.4× iShares MSCI South Korea ETF's market cap, and Merck & Co., Inc. pays a 2.39% dividend while iShares MSCI South Korea ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI South Korea ETF for 46 Days and Merck & Co., Inc. for 98 Days on average.
| EWY | MRK | |
|---|---|---|
Market Cap | $26.25B | $351.28B |
Volume | 19,056,075 | 7,969,665 |
Sector | Broad Market / Factor | Health |
52-Week High | $219.20 | $156.43 |
52-Week Low | $80.72 | $82.49 |
Typical Hold Time | 46 Days | 98 Days |
Enterprise Value | — | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWY (iShares MSCI South Korea ETF) is trading at $176.77, down 3.78% amid broader Asian market pressures. The ETF shows a bearish technical signal with moving averages indicating selling pressure, though oversold RSI levels suggest potential near-term support. Recent volatility reflects sensitivity to semiconductor cycles, with heavy concentration in Samsung and SK hynix driving performance. South Korea's KOSPI has struggled to maintain gains above 7,000 despite AI-driven optimism, facing headwinds from rising oil prices and global bond yields.
The outlook remains tied to semiconductor demand and AI infrastructure spending, with corporate earnings showing resilience. Key risks include concentration in two holdings, memory cycle dependency, and macroeconomic pressures. Governance reforms and visible deleveraging provide fundamental support, but the ETF's high sensitivity to tech sector volatility warrants caution for risk-averse investors.
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
